

Chief Executive Officer
Bristol Myers Squibb Pharmaceuticals Ltd.
BMS House, Uxbridge Business Park
Sanderson Road
Uxbridge
Middlesex
UB8 1DH

Date:

Animal alternatives matter - Corporate investment counts

Dear Chief Executive Officer

As a company that ranks amongst the top 20 pharmaceutical companies, and prides itself on innovation and being at the forefront of research, I'm surprised and extremely disappointed that Bristol Myers Squibb is not a member of the **European Partnership for Animal Alternatives (EPAA)**.

This partnership, composed of leading companies from across 7 different sectors, and representatives from the European Commission, promotes alternative methods that replace, reduce or refine animal testing. These new hi-tech alternative methods are revolutionising safety testing: tissue engineering, cell-on-a-chip technology for toxicity screening, micro-dosing, and computer modelling methods that don't use animals, hold the key to human relevant assays and humane scientific research.

The participation of companies in initiatives such as the EPAA is a key component in ensuring the worldwide research community makes progress towards alternative methods. Centres of excellence, trade organisations, scientific institutes each play a part in this.

I would expect Bristol Myers Squibb to be at the forefront of these efforts.

The involvement of stakeholders in the EPAA is crucial to ensuring validated alternatives are adopted, in shortening the post validation period, and quickening the process of regulatory acceptance.

I would urge you to participate in the European Partnership for Animal Alternatives, without further delay.

The EPAA 's Annual conference is due to be held in November 2008. I hope that you will take that opportunity to become a partner in the EPAA.

Yours sincerely

Address:

.....

.....

.....

.....

Naturewatch supporter

.....Postcode.....